<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00799552</url>
  </required_header>
  <id_info>
    <org_study_id>08-004-03</org_study_id>
    <nct_id>NCT00799552</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye</brief_title>
  <official_title>A Phase II, Multi-Center, Double-Masked, Randomized, Placebo Controlled, Study on the Safety and Efficacy of RX-10045 on the Signs and Symptoms of Dry Eye in Every Day Environmental Conditions and During Provocation Using the Controlled Adverse Environment (CAE) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Resolvyx Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Resolvyx Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of RX-10045 to placebo for
      the treatment of the signs and symptoms of dry eye.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal fluorescein staining and integrated subject diary data</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in dry eye signs and symptoms</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RX-10045</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-10045</intervention_name>
    <description>RX-10045 eye drop</description>
    <arm_group_label>RX-10045</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo eye drop</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age;

          -  Have provided written informed consent;

          -  Have a history of dry eye for at least 6 months prior to enrollment;

          -  Have a history of use or desire to use eye drops for dry eye symptoms within the past
             6 months;

          -  Demonstrate a response when exposed to the CAE.

        Exclusion Criteria:

          -  Have an on-going ocular infection, or active ocular inflammation

          -  Have worn contact lenses within 72 hours of Visit 1 or have anticipated use of contact
             lenses during the study;

          -  Have contact lens-induced dry eye;

          -  Have previously had laser in situ keratomileusis (LASIK) surgery;

          -  Be using or have anticipated use of temporary punctual plugs during the study;

          -  Have best corrected visual acuity &gt; +0.7 in both eyes;

          -  Be a woman who is pregnant, nursing or planning a pregnancy;

          -  Have a known allergy and/or sensitivity to the test article or its components;

          -  Be currently using any medication known to cause ocular drying that is not used on a
             stable dosing regimen for at least 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Research Associates, Andover, MA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Lonsdale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Maine Eye Care, Lewiston, ME</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Geffin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Eye Care Group, Waterbury, CT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ORA Clinical</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.resolvyx.com</url>
  </link>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2008</study_first_submitted>
  <study_first_submitted_qc>November 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2008</study_first_posted>
  <disposition_first_submitted>September 7, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 7, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 20, 2010</disposition_first_posted>
  <last_update_submitted>September 20, 2010</last_update_submitted>
  <last_update_submitted_qc>September 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Per Gjorstrup, Chief Medical Officier</name_title>
    <organization>Resolvyx Pharmaceuticals, Inc</organization>
  </responsible_party>
  <keyword>Keratoconjunctivitis Sicca</keyword>
  <keyword>Dry eye</keyword>
  <keyword>Resolvin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

